Nuvation Bio Inc (NUVB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $1.41B
Last updated: Nov 17, 2026 at 4:43 PM ET
Nuvation Bio Inc (NUVB) Statistics
Nuvation Bio (NUVB) has a market cap of $1.41B and an enterprise value of $1.54B. Revenue grew 968.77% over the last 12 months from the 12 months before. It kept -67.38% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 9.35% above the market cap, as debt exceeds cash.
| Market Cap | $1.41B |
|---|---|
| Enterprise Value | $1.54B |
| Latest price (Nov 17, 2026) | $3.91 |
Key Dates
| Last Earnings Date | Nov 4, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.8x and 6.0x.
| P/S Ratio | 6.8x |
|---|---|
| Forward P/S | 6.9x |
| P/B Ratio | 6.0x |
| P/TBV Ratio | 6.6x |
Price Statistics
The stock is down 19.55% over 52 weeks and trades 22.11% below its 50-day average.
| Beta (1Y) | 1.74 |
|---|---|
| 52-Week Change | -19.55% |
| 1-Month Change | -12.72% |
| 3-Month Change | -46.14% |
| 6-Month Change | -7.78% |
| 5-Year Change | -48.09% |
| Total Return (1Y) | -19.55% |
| Total Return (3Y CAGR) | +41.49% |
| Total Return (5Y CAGR) | -16.17% |
| Return vs SPY (1Y) | -30.10% |
| Max Drawdown (1Y) | -59.75% |
| Max Drawdown (3Y) | -59.75% |
| Sharpe Ratio (1Y) | -0.26 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $5.02 |
| 200-Day Average | $5.31 |
| 52-Week Range | $3.82 to $9.75 |
| RSI (14 Days) | 32.4 |
| Average Volume (20 Days) | 5.21M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.45x current liabilities, and total debt is 1.25x shareholder equity.
| Current Ratio | 7.45x |
|---|---|
| Quick Ratio | 7.30x |
| Debt / Equity | 1.25x |
| Interest Coverage | -3.40x |
Returns and Efficiency
Return on invested capital is -18.68% over the last 12 months, against a 5-year average of -73.36%.
| Return on Equity (ROE) | -59.63% |
|---|---|
| Return on Assets (ROA) | -17.46% |
| Return on Invested Capital (ROIC) | -18.68% |
| Return on Capital Employed (ROCE) | -17.85% |
| ROE (5Y Average) | -45.89% |
| ROA (5Y Average) | -35.67% |
| ROIC (5Y Average) | -73.36% |
| Asset Turnover | 0.29x |
| Receivables Turnover | 6.27x |
| Cash Conversion Cycle | -254 days |
Scores
NUVB has an Altman Z-Score of 0.04, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.04 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $201.73M over the last 12 months.
| Revenue | $201.73M |
|---|---|
| Revenue Growth (YoY) | +968.77% |
| Gross Profit | $209.75M |
| Operating Income | -$123.40M |
| Pretax Income | -$135.93M |
| Net Income | -$135.93M |
| EBITDA | -$121.54M |
| EBIT | -$121.36M |
| Reported EPS (TTM) | -$0.37 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 29.29% of the $778.39M in total assets.
| Cash and Equivalents | $153.77M |
|---|---|
| Total Debt | $285.43M |
| Net Debt | $131.66M |
| Net Debt Per Share | $0.37 |
| Working Capital | $636.10M |
| Shareholder Equity | $227.97M |
| Book Value Per Share | $0.65 |
| Tangible Book Value | $208.18M |
| Tangible Book Per Share | $0.59 |
| Total Assets | $778.39M |
| Total Liabilities | $550.42M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.98M of capital spending, operating cash flow left -$108.17M of free cash flow.
| Operating Cash Flow | -$106.19M |
|---|---|
| Capital Expenditures | $1.98M |
| Free Cash Flow | -$108.17M |
| FCF Per Share | -$0.31 |
| Depreciation and Amortization | $4.55M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -61.17%.
| Gross Margin | 103.98% |
|---|---|
| Operating Margin | -61.17% |
| Pretax Margin | -67.38% |
| Net Margin | -67.38% |
| EBITDA Margin | -60.25% |
| EBIT Margin | -60.16% |
| FCF Margin | -53.62% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -43.33% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -44.38% |
Dividends and Yields
NUVB does not pay a dividend. Its free cash flow yield is -7.86%.
| FCF Yield | -7.86% |
|---|---|
| Buyback Yield | -0.06% |
| Shareholder Yield | -0.06% |
Peer Position
Against 8 similar companies, NUVB has the 4th highest P/S.
P/S RatioPeer median 4.2x
ROICPeer median -66.62%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -1.91%
| P/S Ratio | 6.8x vs 4.2x median |
|---|---|
| ROIC | -18.68% vs -66.62% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +968.77% vs -1.91% median |
Analyst Forecast
Consensus estimates put revenue growth at 99.71% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +99.71% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About NUVB
What is NUVB's market cap?
Nuvation Bio has a market cap of $1.41B. Its enterprise value, which adds debt and subtracts cash, is $1.54B.
How many shares of NUVB are outstanding?
Nuvation Bio has 351.86M shares outstanding. The count is up 2.77% from a year earlier.
Does NUVB pay a dividend?
No. Nuvation Bio does not pay a dividend.
How much debt does NUVB have?
Nuvation Bio has $285.43M of total debt and $153.77M of cash and equivalents, a net debt position of $131.66M.
NUVB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors